Other
Fruquintinib
0
Pipeline Programs↗
5
Active Trials↗
0
Companies Involved↗
Fruquintinib is an early-stage landscape with 0 programs across 0 companies.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
15
clinical trials
Completed8 · 53%
Recruiting4 · 27%
Unknown status2 · 13%
Not yet recruiting1 · 7%
Clinical Trials
Trial Activity
15 trials
Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC
Recruiting·—·Phase 2·NCT06427005·66 enrolled
Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC
Recruiting·—·N/A·NCT06551207·80 enrolled
SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC
Not yet recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT05747716·44 enrolled
A Phase II Study on Dose Optimization of Fruquintinib in Elderly mCRC Patients Refractory to Standard Treatment（DOFEMCRC）
Completed·—·Phase 2·NCT05025631·29 enrolled
Fruquintinib in the Cross-line Treatment of Refractory mCRC
Unknown status·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·N/A·NCT06099314·36 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)